OncoMatch/Clinical Trials/NCT07192185
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
Is NCT07192185 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including FOLFOX and Atezolizumab & Bevacizumab for hepatocellular carcinoma (hcc).
Treatment: FOLFOX · Atezolizumab & Bevacizumab — Atezolizumab plus bevacizumab is the first-line treatment for advanced hepatocellular carcinoma (HCC). However, the effect of the second-line treatment after the progress of Atezolizumab plus bevacizumab therapy remains unsatisfactory. This is a prospective trial to investigate the efficacy and safety of systemic chemotherapy with FOLFOX plus Atezolizumab \& bevacizumab as second-line treatment for patients with advanced HCC who previously received atezolizumab plus bevacizumab
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: anti-PD-L1 therapy (atezolizumab) — first-line
Patients who have previously received first-line treatment with atezolizumab plus bevacizumab and who have shown tumor progression as confirmed by imaging studies.
Must have received: VEGF inhibitor (bevacizumab) — first-line
Patients who have previously received first-line treatment with atezolizumab plus bevacizumab and who have shown tumor progression as confirmed by imaging studies.
Cannot have received: systemic therapy
Exception: atezolizumab plus bevacizumab
No other systemic treatments have been administered.
Lab requirements
Blood counts
Hemoglobin ≥ 8.5 g/dL; Absolute neutrophil count (ANC) >1,500/mm3
Kidney function
Serum creatinine ≤ 1.5 x upper limit of normal
Liver function
Total bilirubin ≤ 30mmol/L; Serum albumin ≥ 30 g/L; ASL and AST ≤ 5 x upper limit of normal; INR ≤ 1.5 or PT/APTT within normal limits; No cirrhosis or cirrhotic status of Child-Pugh class A only
Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/L Serum albumin ≥ 30 g/L ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) >1,500/mm3
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07192185 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages